Montelukast as a Controller of Atopic Syndrome

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to find out if montelukast can be used to treat the various symptoms of allergic syndrome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Helsinki University; University of Helsinki
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Wheal diameter at least 4 mm in skin-prick test for both birch and timothy

• Allergic symptoms in both upper airways (allergic rhinitis) and lower airways (asthma-like symptoms or diagnosed asthma) and at least one of the following:

• Allergic conjunctivitis

• Atopic eczema

• Oral symptoms from vegetables or fruits by cross reactivity to birch

• Urticaria in allergen exposure

Exclusion Criteria:

• Need for regular treatment with glucocorticoids

• Current smoking

• Other major disease or need for regular drug treatment

• Pregnancy